Pharmaceuticals: EU Regulations

This course provides an overview of the regulations and legislative framework, as well as the EMA entities responsible for medicinal product reviews.

The European Union (EU) unifies 27 Member States plus three countries (Iceland, Liechtenstein, and Norway) in the European Economic Area (EEA), providing a single market for the pharmaceutical industry. The EU’s directives and regulations outline the requirements for the development, manufacture, and marketing of medicinal products for human and veterinary use. These requirements are distinct from those for the development and authorisation of medical devices and in vitro diagnostics in the EU. High standards of quality, safety, and efficacy must be met for a product to be granted a Marketing Authorisation (MA). The European Medicines Agency (EMA) is a decentralised organisation responsible for the scientific evaluation of EU Marketing Authorisation Applications for human and veterinary medicines through the Centralised Procedure (CP). Within individual Member States, designated Competent Authorities assess marketing applications and monitor compliance for medicinal products submitted under the Mutual Recognition Procedure (MRP), Decentralised Procedure (DCP), and National Procedure (NP).

This course provides an overview of the regulations and legislative framework, as well as the EMA entities responsible for medicinal product reviews. The different application and registration procedures are described, followed by an explanation of the regulatory requirements for a product’s lifecycle, including marketing and postmarketing requirements, and prescription-to-over-the-counter (OTC) switches. The enforcement of regulations through inspections and other compliance activities is also addressed.

On 20 November 2017, European Union (EU) Member States decided to relocate the EMA from London to Amsterdam in the Netherlands as a result of the United Kingdom's (UK) withdrawal from the EU. EMA left its London premises on 1 March 2019 to relocate to Amsterdam. Since 4 March 2019, the official address of the Agency is that of its permanent building in Amsterdam Zuidas.

At a Glance

Target Audience: This course is beneficial for regulatory and quality-assurance professionals seeking to learn the basics of EU pharmaceutical laws and regulations and their implementation into national laws in the individual EU Member States.

Learning Level: Basic

Total Length of Course: 6 Hours

RAC Points: 6

Pharmaceutical Certificate Elective

Enrollment Period: 12 months

Learning Objectives

Outline the EMA framework and identify key players for pharmaceutical development and registration.

Describe the unique elements of the EU directives and regulations.

Describe the medicinal product legislative framework and associated regulations, including Good Manufacturing Practices (GMPs), Good Clinical Practices (GCPs), Good Laboratory Practices (GLPs), Good Distribution Practices (GDPs), Good Pharmacovigilance Practices (GVPs), clinical trials regulation, Competent Authority inspections, and Mutual Recognition Agreements (MRAs).

Explain the medicinal products registration procedures—Centralised Procedure (CP), Mutual Recognition Procedure (MRP), Decentralised Procedure (DCP), and National Procedure (NP).

Identify EMA’s scientific device procedures.

Define and describe advertising and promotion regulations for medicinal products.

Outline key EU postmarketing activities, including requirements for postmarket surveillance.

Define over-the-counter (OTC) product and prescription-to-OTC switches.

Explain types of enforcement activities for medicinal product regulations.

Lesson Titles

Lesson 1: Overview of the EU Regulatory Framework

Lesson 2: Pharmaceutical Regulation and Legislation

Lesson 3: Medicinal Products Registration Procedures

Lesson 4: Over-the-Counter (OTC) Products

Lesson 5: Advertising and Promotion of Medicinal Products

Lesson 6: Postmarketing Activities